BCL2 and neoplasm: WB results revealed that X-ray (compared with the control group) and Pembrolizumab (compared with the 1 Gy group) and miR-20b-5p overexpression (compared with the 1 Gy+1 μM group) evidently restrained the protein expression of PD-L1 and PD1, hampered Bax and Caspase-3 levels and elevated the bcl-2 expression in tumor tissues (P < 0.05, Figure 6(e,f)).